Piyanuch Kongtim is an Oncology physician affiliated with University of California, Irvine. OpenAlex indexes 143 publications with 2,277 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S
Orange, CA 928683201
Telephone
714-880-7812Provider last certified this registry record 28 Feb 2023.
Clinical trials
- CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
Sponsor: University of California, Irvine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
24.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.9%Acyclovir100%Part D≥15 patientsCancer & immunology
23.1%Thalidomide Analog16.6%Lenalidomide57%Pomalyst43%Part D<11 patientsLeukocyte Growth Factor6.5%Zarxio100%Part D<11 patientsMetabolism & gastrointestinal
17.2%Serotonin-3 Receptor Antagonist10.7%Ondansetron Hcl100%Part D≥13 patientsPotassium supplement6.5%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
Biology of Blood and Marrow Transplantation
2024 - Adoptive cellular therapy after hematopoietic stem cell transplantation
American Journal of Hematology
2024 - Anakinra versus etoposide‐based therapy added to high‐dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis
European Journal Of Haematology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Stefan Ciurea, MD
University of California, Irvine
Farshid Dayyani, MD
University of California, Irvine
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”